埃克替尼治疗晚期非小细胞肺癌患者的效果

Effect of Icotinib for Patients with Advanced Non-small Cell Lung Cancer

目的分析在晚期非小细胞肺癌患者治疗过程中使用埃克替尼的临床效果与预后。方法回顾分析2017年1月至2019年12月葫芦岛市中心医院收治的78例晚期非小细胞肺癌患者的临床资料,根据治疗方法的不同分为对照组和研究组,每组39例。对照组患者采用吉非替尼进行治疗,研究组患者采用埃克替尼进行治疗,比较两组患者的临床治疗效果、无进展生存期及不良反应发生情况。结果研究组患者病情缓解率(25.64%)略高于对照组(23.08%),差异无统计学意义(P> 0.05);研究组患者的无进展生存期为(8.25±0.58)个月,对照组患者的无进展生存期为(8.34±0.66)个月,差异无统计学意义(P> 0.05);研究组患者的不良反应率(17.95%)略低于对照组(23.08%),差异无统计学意义(P> 0.05)。结论在晚期非小细胞肺癌患者治疗过程中应用埃克替尼和吉非替尼具有相当的疗效和安全性,且应用埃克替尼治疗的患者不良反应发生率略低。

Objective To analyze the clinical effects and prognosis of icotinib in the treatment of patients with advanced non-small cell lung cancer.Methods Retrospectively analyzed the clinical data of 78 patients with advanced non-small cell lung cancer admitted to our hospital from January 2017 to December 2019,and they were divided into two groups according to diff erent treatment methods,with 39 cases in each group.Patients in the control group were treated with gefi tinib,and patients in the study group were treated with icotinib.The clinical treatment effect,progression-free survival time and incidence of adverse reactions were analyzed.Results The response rate of the study group was 25.64%,and the control group was 23.08%,the diff erence was not statistically signifi cant(P>0.05).The progression-free survival of the study group was(8.25±0.58)months,the control was(8.34±0.66)months,the diff erence between the two groups was not signifi cant(P>0.05).The adverse reaction rate of the study group was 17.95%,and the control group was 23.08%,the difference was not statistically signifi cant(P>0.05).Conclusion In the treatment of patients with advanced non-small cell lung cancer,the use of icotinib and gefitinib has considerable efficacy and safety,and the incidence of adverse reactions of icotinib is slightly lower.